ArticleAPL bioengineering2020
3D bioprinting and its potential impact on cardiac failure treatment: An industry perspective.
Article in APL bioengineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- Insights into the molecular mechanism of pulmonary vein stenosis in pediatric patients with congenital heart disease.JTCVS open · 2025Article
- Considering the Risks and Costs of Solid Organ Xenotransplantation.Advanced biology · 2025Article
- Development of Novel 3D Spheroids for Discrete Subaortic Stenosis.Cardiovascular engineering and technology · 2024Article
- Recent advances in soluble decellularized extracellular matrix for heart tissue engineering and organ modeling.Journal of biomaterials applications · 2023Review
- The Progress in Bioprinting and Its Potential Impact on Health-Related Quality of Life.Bioengineering (Basel, Switzerland) · 2023Review
- In vitro high-content tissue models to address precision medicine challenges.Molecular aspects of medicine · 2023Review
- 3D-bioprinted cardiac tissues and their potential for disease modeling.Journal of 3D printing in medicine · 2023Article
- (Bio)printing in Personalized Medicine-Opportunities and Potential Benefits.Bioengineering (Basel, Switzerland) · 2023Review
- Recent advances in biological pumps as a building block for bioartificial hearts.Frontiers in bioengineering and biotechnology · 2023Review
- Expanding Quality by Design Principles to Support 3D Printed Medical Device Development Following the Renewed Regulatory Framework in Europe.Biomedicines · 2022Review
- Editorial Series conclusion and journal outlook.APL bioengineering · 2022Article
- Recent Advances in Designing Electroconductive Biomaterials for Cardiac Tissue Engineering.Advanced healthcare materials · 2022Review
- Taking It Personally: 3D Bioprinting a Patient-Specific Cardiac Patch for the Treatment of Heart Failure.Bioengineering (Basel, Switzerland) · 2022Review
- Current state of the art in hypoplastic left heart syndrome.Frontiers in cardiovascular medicine · 2022Review
- Prospect of 3D bioprinting over cardiac cell therapy and conventional tissue engineering in the treatment of COVID-19 patients with myocardial injury.Regenerative therapy · 2021Review
- Bioprinting Technology in Skin, Heart, Pancreas and Cartilage Tissues: Progress and Challenges in Clinical Practice.International journal of environmental research and public health · 2021Review
- Biophysics of biofabrication.APL bioengineering · 2021Article
- Advances in 3D bioprinting technology for cardiac tissue engineering and regeneration.Bioactive materials · 2021Review
- New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity.Frontiers in pharmacology · 2021Review
- Current state and future of 3D bioprinted models for cardiovascular research and drug development.ADMET & DMPK · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3D printing technologies are emerging as a disruptive innovation for the treatment of patients in cardiac failure. The ability to create custom devices, at the point of care, will affect both the diagnosis and treatment of cardiac diseases. The introduction of bioinks containing cells and biomaterials and the development of new computer assisted design and computer assisted manufacturing systems have ushered in a new technology known as 3D bioprinting. Small scale 3D bioprinting has successfully created cardiac tissue microphysiological systems. 3D bioprinting provides an opportunity to evaluate the assembly of specific parts of the heart and most notably heart valves. With the continuous development of instrumentation and bioinks and a complete understanding of cardiac tissue development, it is proposed that 3D bioprinting may permit the assembly of a heart described as a total biofabricated heart.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.